MedLife (M) Q4 2025 earnings summary

Executive summary

• Consolidated pro-forma turnover reached RON 3.17 billion in 2025, up 16.8%–17% year-over-year, driven by organic growth and acquisitions.

• Pro-forma EBITDA rose 16.3% to RON 459.4 million, supported by strong demand, new capacity, and acquisitions.

• Major acquisitions included Routine Med (Tulcea), All Clinic (Moldova), and Medstar (Cluj-Napoca), expanding national and international presence.

• Hospitals and laboratories led performance, with clinics also contributing, reflecting resilience amid challenging economic conditions.

• Significant investments included a new hyperclinic in Pitesti and a Neolife oncology center in Bacau.

Financial highlights

• Pro-forma net result was RON 8.5 million, a 49.2% decrease versus 2024, while statutory net result showed a loss of RON 3.95 million due to FX losses.

• IFRS revenues increased 16.8% year-over-year, with EBITDA margin at 14% (15.8% pro-forma).

• Operating expenses as a percentage of sales rose to 94.99%–95.4%, mainly due to higher consumables and salaries.

• Net cash from operating activities decreased by 22.4% to RON 221.7 million, mainly due to working capital changes.

• RON 235.7 million allocated to investing activities, including acquisitions and major CAPEX projects.

Outlook and guidance

• Management expects continued growth through organic development and acquisitions, supported by increased credit facilities.

• Sufficient liquidity is projected for at least twelve months, with ongoing focus on efficiency and capitalizing on market opportunities.

• Focus remains on operational efficiency, strategic investments, and leveraging AI and digital technologies.

• Plans to scale up genetic testing and pursue further acquisitions in complementary healthcare fields.